SynthesisClinical cardiology2010
The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis.
Synthesis in Clinical cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Mineralocorticoid receptor antagonists for acute myocardial infarction: a systematic review and meta-analysis of randomised controlled trials.Open heart · 2025Pooled it
- Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.European journal of heart failure · 2022Trial
- Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.European heart journal · 2021Trial
- Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial.Upsala journal of medical sciences · 2021Trial
- The Role of Infarct Border Zone Remodelling in Ventricular Arrhythmias: Bridging Basic Research and Clinical Applications.Journal of cellular and molecular medicine · 2025Review
- Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.European heart journal. Cardiovascular pharmacotherapy · 2023Article
- Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Review
- Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?Journal of clinical medicine · 2019Article
- Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?Current hypertension reports · 2019Review
- Review
- Aldosterone-to-Renin Ratio Is Associated With Reduced 24-Hour Heart Rate Variability and QTc Prolongation in Hypertensive Patients.Medicine · 2016Article
- Kcne3 deletion initiates extracardiac arrhythmogenesis in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new.American journal of cardiovascular disease · 2012Article
- New paradigms in the prevention of sudden cardiac arrest and heart failure treatment.Current cardiology reports · 2011Review
- Effect of spironolactone on ventricular arrhythmias in patients with left ventricular systolic dysfunction and implantable cardioverter defibrillators.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSudden cardiac death (SCD) from cardiac arrest, one of the most common types of cardiac-related death, is most often triggered by ventricular arrhythmia (VA). It has been reported that aldosterone antagonists (AAs) have the benefit of reducing SCD in patients with heart failure (HF). It also has been indicated in animal experiments and clinical trials that AAs may have an antiarrhythmic effect. HYPOTHESIS: AAs have an effect on VA in patients with HF or coronary artery disease.
methodsWe searched the Cochrane Central Register of Controlled Trials, PubMed, Current Controlled Trials, and the National Research Register, and identified randomized controlled trials on the effect of AAs on VA.
resultsAll together, 7 trials with a total of 8635 patients were identified and extracted. AAs reduced the risk of SCD in patients with HF by 21% (relative risk [RR]: 0.79, 95% confidence interval [CI]: 0.67-0.93). AAs significantly reduced the episodes of ventricular premature complexes (mean difference 705 ± 646 episodes per 24 hours). Risk of ventricular tachycardia was reduced by 72% (RR: 0.28, 95% CI: 0.10-0.77).
conclusionsThe additional administration of AAs in patients with HF or coronary artery disease shows a benefit in reducing the risk of SCD and may also be effective for reducing episodes of ventricular premature complexes and ventricular tachycardia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.